Inflammation and large arteries: Potential mechanisms for inflammation-induced arterial stiffness

Elsevier BV - Tập 6 - Trang 59-64 - 2012
Kaisa M. Mäki-Petäjä1, Ian B. Wilkinson1
1Clinical Pharmacology Unit, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK

Tóm tắt

Systemic inflammatory conditions are associated with an increased risk of cardiovascular disease (CVD). How exactly inflammation leads to this is not fully understood, but it has been suggested that arterial stiffening, could provide potential mechanisms to explain it. Chronic, systemic inflammatory conditions, as well as acute-models of inflammation are associated with arterial stiffening. Moreover, aortic stiffness can be reversed with successful immunomodulatory therapy. Although it seems evident that inflammation is involved in the process of aortic stiffening, the precise mechanism responsible for this remains unclear. There are number of possible mechanisms by which inflammation could lead to arterial stiffening. (1) Inflammation is associated with endothelial dysfunction and this can regulate arterial stiffness via changes in smooth muscle tone. (2) Inflammation leads to increased synthesis of matrix metalloproteinases, which can degrade elastin, resulting in stiffening. (3) Several mediators of inflammation may directly stimulate vascular calcification, whereas endogenous inhibitors of vascular calcification are downregulated during inflammation, both of which can lead to stiffening. (4) During inflammation arterial glycosaminoglycan (GAG) synthesis is upregulated. In animal models, an overproduction of certain GAGs in the aorta results in stiffening of the arterial wall by thinning of elastic lamellae. (5) Finally, direct vascular inflammation could lead to arterial stiffening by changing the composition of extracellular matrix. This review aims to discuss potential mechanisms by which inflammation could lead to aortic stiffening.

Tài liệu tham khảo

Libby P. Inflammation in atherosclerosis. Nature 2002 December 19;420:868–74.

Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994 August 18;331:417–24.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 November 14;347:1557–65.

Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000 August 29;102:994–9.

Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004 May;24:969–74.

Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006 November;27:2588–605.

Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001 May;37:1236–41.

Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999 May 11;99:2434–9.

Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001 October;12:2117–24.

Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001 February 20;103:987–92.

Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999 May;33:1111–7.

Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 March 7;113:1213–25.

Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002 January;39:10–5.

Laurent S, Katsahian S, Fassot C, Tropeano AI, GautierI, Laloux B, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003 May;34:1203–6.

Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002 October 15;106: 2085–90.

Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001 December;21:2046–50.

Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, et al. Pulse wave velocity predicts cardiovascular mortality: findings from the HawaiieLos AngeleseHiroshima study. Circ J 2005 March;69:259–64.

Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006 February 7;113:664–70.

Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006 February 7;113:657–63.

Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010 March 30;55:1318–27.

Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994 April;37:481–94.

Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002 April;46:862–73.

del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001 December;44:2737–45.

Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998 June;25: 1072–7.

Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999 November 23;100: 2124–6.

Maki-Petaja KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, Harish S, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006 September 12;114:1185–92.

Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003 January;48:72–80.

Booth AD, Wallace S, McEniery CM, Yasmin, Brown J, Jayne DR, Wilkinson IB. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004 February;50:581–8.

Wallace SM, Maki-Petaja KM, Cheriyan J, Davidson EH, Cherry L, McEniery CM, et al. Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. Br J Clin Pharmacol 2010 December;70:799–806.

Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010 February;55:333–8.

Maki-Petaja KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007 August 28;50:852–8.

Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002 October 1;22:1637–41.

Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000 May;98:531–5.

Yki-Jarvinen H, Bergholm R, Leirisalo-Repo M. Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann Rheum Dis 2003 July;62:630–4.

Gunnett CA, Lund DD, McDowell AK, Faraci FM, Heistad DD. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler Thromb Vasc Biol 2005 August;25:1617–22.

Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002 September 17;106:1439–41.

Fichtlscherer S, Breuer S, Schachinger V, Dimmeler S, Zeiher AM. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 2004 August;25:1412–8.

Xu J, Xie Z, Reece R, Pimental D, Zou MH. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol 2006 December;26:2688–95.

Rabelink TJ, Luscher TF. Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol 2006 February;26:267–71.

Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001 March 6;103:1282–8.

Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003 June 20;278:22,546–22,554.

Cosentino F, Katusic ZS. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995 January 1;91:139–44.

Kinoshita H, Tsutsui M, Milstien S, Katusic ZS. Tetrahy-drobiopterin, nitric oxide and regulation of cerebral arterial tone. Prog Neurobiol 1997 July;52:295–302.

Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998 August 4;95:9220–5.

Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of athero-thrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002 May;29:875–82.

Savage CO, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Auto-antibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward culturedendothelial cells.Am J Pathol 1992 August;141:335–42.

Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983 August;24:1070–6.

Wallace SM, Yasmin, McEniery CM, Maki-Petaja KM, Booth AD, Cockcroft JR, Wilkinson IB. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension 2007 July;50:228–33.

Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002 January 15;105:213–7.

Schmitt M, Avolio A, Qasem A, McEniery CM, Butlin M, Wilkinson IB, et al. Basal NO locally modulates human iliac artery function in vivo. Hypertension 2005 July;46:227–31.

Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodriguez JA, et al. C-reactive protein induces matrix metalloproteinase-1 and –10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006 April 4; 47:1369–78.

Yasmin, Wallace S, McEniery CM, Dakham Z, Pusalkar P, Maki-Petaja K, Ashby MJ, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005 February;25:372.

Vlachopoulos C, Aznaouridis K, Dima I, Ioakeimidis N, Vasiliadou C, Zervoudaki A, et al. Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults. Int J Cardiol 2007 November 30;122:232–8.

Yasmin, McEniery CM, O’Shaughnessy KM, Harnett P, Arshad A, Wallace S, Maki-Petaja K, et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006 August;26:1799–805.

Martyn CN, Greenwald SE. Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension. Lancet 1997 September 27;350:953–5.

Moe SM, Chen NX. Inflammation and vascular calcification. Blood Purif 2005;23:64–71.

Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 2004 August; 19(Suppl. 5):V59–66.

Ford ML, Tomlinson LA, Smith ER, Rajkumar C, Holt SG. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant 2010 June;25:1853–8.

Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008 October;23: 3263–71.

Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002 November;8:1249–56.

Raines EW. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol 2000 June;81:173–82.

Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003 July;57: 195–202.

Kaji T, Hiraga S, Yamamoto C, Sakamoto M, Nakashima Y, Sueishi K, et al. Tumor necrosis factor alpha-induced alteration of glycosaminoglycans in cultured vascular smooth-muscle cells. Biochim Biophys Acta 1993 March 10;1176:20–6.

Toole BP, Wight TN, Tammi MI. Hyaluronanecell interactions in cancer and vascular disease. J Biol Chem 2002 February 15; 277:4593–6.

Chai S, Chai Q, Danielsen CC, Hjorth P, Nyengaard JR, Ledet T, et al. Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis. Circ Res 2005 March 18;96:583–91.

Li D, Fayad ZA, Bluemke DA. Can contrast-enhanced cardiac magnetic resonance assess inflammation of the coronary wall? JACC Cardiovasc Imaging 2009 May;2:589–91.

Hofmann LV, Liddell RP, Eng J, Wasserman BA, Arepally A, Lee DS, et al. Human peripheral arteries: feasibility of trans-venous intravascular MR imaging of the arterial wall. Radiology 2005 May;235:617–22.

Ng WF, Fantin F, Ng C, Dockery F, Schiff R, Davies KA, et al. Takayasu’s arteritis: a cause of prolonged arterial stiffness. Rheumatology (Oxford) 2006 June;45:741–5.

Yokoyama H, Kawasaki M, Ito Y, Minatoguchi S, Fujiwara H. Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity. J Am Coll Cardiol 2005 December 6;46:2031–7.

Senzaki H, Chen CH, Ishido H, Masutani S, Matsunaga T, Taketazu M, et al. Arterial hemodynamics in patients after Kawasaki disease. Circulation 2005 April 26;111:2119–25.

Cheung YF, Ho MH, Tam SC, Yung TC. Increased high sensitivity C reactive protein concentrations and increased arterial stiffness in children with a history of Kawasaki disease. Heart 2004 November;90: 1281–5.

Rheumatoid vasculitis. Johns Hopkins Vasculitis Centre, http://vasculitis.med.jhu.edu/types/rheumatoid.html; 2007. Ref type: internet communication.

Watts RA, Carruthers DM, Symmons DP, Scott DG. The incidence of rheumatoid vasculitis in the Norwich Health Authority. Br J Rheumatol 1994 September;33: 832–3.

Gravallese EM, Corson JM, Coblyn JS, Pinkus GS, Weinblatt ME. Rheumatoid aortitis: a rarely recognized but clinically significant entity. Medicine (Baltimore) 1989 March;68: 95–106.

Hollan I, Prayson R, Saatvedt K, Almdahl SM, Nossent HC, Mikkelsen K, et al. Inflammatory cell infiltrates in vessels with different susceptibility to atherosclerosis in rheumatic and non-rheumatic patients: a controlled study of biopsy specimens obtained at coronary artery surgery. Circ J 2008 December;72: 1986–92.

Thông tin
Thông tin xuất bản

Elsevier BV

Tập 6

59-64

Thông tin tác giả